Research
Hormonal
GLP-1 based therapies carry class-wide safety warnings including gastrointestinal effects, gallbladder events, pancreatitis risk, and a boxed warning for medullary thyroid carcinoma based on rodent data.
These medications work well but can cause nausea, vomiting, or other GI issues. Your doctor will start you on a low dose and slowly increase it to help your body adjust. If you have a family history of specific thyroid cancers, you cannot take these drugs.
StrongQualifiesHIGH confidence
Common side effects encountered include gastrointestinal (GI) symptoms. GLP-1-based drugs carry warnings for gallbladder events and rare pancreatitis. They also carry a class boxed warning about medullary thyroid carcinoma based on rodent data
Why this rating
Based on FDA labeling and pivotal trial safety data cited in the review.
Source
Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies
Syed S Raza et al. · Cureus · 2025
DOI 10.7759/cureus.96739
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.Strong
- Access to effective obesity pharmacotherapy is severely limited by cost, insurance prior authorization, and systemic inequities, leading to high discontinuation rates.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →